Akero Therapeutics Inc (AKRO)
19.95
+0.26
(+1.32%)
USD |
NASDAQ |
May 03, 10:47
Akero Therapeutics Cash from Investing (Quarterly): 12.79M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.79M |
| September 30, 2023 | -125.70M |
| June 30, 2023 | -128.30M |
| March 31, 2023 | 17.59M |
| December 31, 2022 | -101.44M |
| September 30, 2022 | 3.00M |
| June 30, 2022 | 11.87M |
| March 31, 2022 | 22.75M |
| December 31, 2021 | 12.00M |
| September 30, 2021 | 21.93M |
| June 30, 2021 | -10.65M |
| March 31, 2021 | 19.00M |
| Date | Value |
|---|---|
| December 31, 2020 | 17.90M |
| September 30, 2020 | -59.84M |
| June 30, 2020 | 38.46M |
| March 31, 2020 | -6.281M |
| December 31, 2019 | -71.51M |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | -5.00M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-128.30M
Minimum
Jun 2023
38.46M
Maximum
Jun 2020
-17.18M
Average
3.00M
Median
Sep 2022
Cash from Investing (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | -362.12M |
| 89bio Inc | -63.64M |
| Viking Therapeutics Inc | -459.79M |
| Eli Lilly and Co | -1.178B |
| Ionis Pharmaceuticals Inc | -26.71M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -48.63M |
| Cash from Financing (Quarterly) | 0.502M |
| Free Cash Flow | -145.37M |
| Free Cash Flow Per Share (Quarterly) | -0.8722 |
| Free Cash Flow Yield | -13.87% |